NJK14047
NJK14047 inhibits p38 MAPK and the differentation of naive T-cells to Th1 and Th17 cells. NJK14047 ameliorates the collage-induced rheumatoid arthritis and Imiquimod -induced psoriasis in mice[1].
Product Specifications
CAS Number
1800576-41-3
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
P38 MAPK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/njk14047.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC(C2=CC=C(C(C3=CC=C(OCC(O)CO)C=C3)=O)C=C2)=C(C)C=C1)NC4CC4
Molecular Formula
C27H27NO5
Molecular Weight
445.51
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Lee JH, et al., NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation. Int Immunopharmacol. 2024 Mar 30;130:111800.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400447-500 1x 500 µL
DOG-1 (DG1/447), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400908-500 1x 500 µL
Tyrosinase (T311 + OCA1/812), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
